TABLE 2.

Distortion product otoacoustic emissions levels and level shifts at 3175 Hz for 18 cisplatin patients tested after 120 to 200 mg cumulative dose of cisplatin

ID	Dose	Baseline dB SPL	Follow-Up dB SPL	OAE Shift	Baseline h(dB SPL)	Follow-Up h(dB SPL)	Shift in Transformed OAEs
A	150	−3.1	−2.4	0.8	−3.0	−2.3	0.7
B	190	−5.1	−13.3	−8.2	−4.7	−11.0	−6.2
C	160	−13.7	−7.9	5.8	−11.2	−7.0	4.2
D	150	−5.1	−3.2	1.9	−4.7	−3.1	1.7
E	120	−12.5	−9.4	3.1	−10.4	−8.2	2.2
F	120	−18.5	−8.5	9.9	−14.2	−7.5	6.7
G	190	−13.6	−18.9	−5.2	−11.2	−14.4	−3.2
H	200	−11.4	−10.1	1.3	−9.7	−8.7	0.9
I	200	−11.8	−12.4	−0.6	−10.0	−10.4	−0.4
J	200	−0.7	−7.5	−6.8	−0.7	−6.7	−6.0
K	190	−14.8	−9.2	5.6	−12.0	−8.1	3.9
L	132	−0.1	4.1	4.2	−0.0	4.4	4.5
M	120	−5.6	−4.9	0.7	−5.2	−4.6	0.6
N	170	−5.4	−9.0	−3.5	−5.0	−7.8	−2.9
O	180	−4.0	−5.0	−1.0	−3.8	−4.6	−0.9
P	160	−7.9	−11.5	−3.6	−7.1	−9.7	−2.7
Q	160	0.3	2.5	2.2	0.3	2.6	2.3
R	200	−6.5	−8.2	−1.8	−5.9	−7.3	−1.4

OAE, otoacoustic emissions.